Lilly (LLY.US) heavy new drug "telaprevir" new indications have applied for listing in China.

The latest announcement on the website of China's National Medical Products Administration Drug Evaluation Center (CDE) reveals that Eli Lilly's blockbuster drug GIP/GLP-1 receptor dual agonist tirzepatide injection has applied for a new indication and has been accepted for review, but the specific indication has not been disclosed. According to the official website of CDE, this is the third application for market approval of tirzepatide in China. Public information shows that tirzepatide is a glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is injected once a week. The product was approved by the FDA in May 2022 and November 2023 for the treatment of diabetes as well as obesity and overweight patients. In China, tirzepatide was approved for its first indication for blood sugar control in adult type 2 diabetes patients in May this year. In July, the product was approved by the NMPA for long-term weight management in overweight patients with obesity or at least one weight-related comorbidity.